Skip to main content

Advertisement

SpringerLink
Log in

The clinical implications of ageing for rational drug therapy

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Introduction

The proportion of the elderly is constantly increasing and by the year 2025 20% of the population will be above 65 years of age. With advanced age, subjects will develop multiple diseases and often need to take several drugs.

Discussion

This polypharmacy increases the risk for drug interactions and adverse effects. In addition, age-related physiological changes affect different biological systems and can contribute to alterations in pharmacokinetics and pharmacodynamics in older patients, which are more often seen in the frail than in the fit elderly. These features will complicate drug therapy in the elderly, and a careful dose titration is advisable. Furthermore, inappropriate drug prescription and non-adherence to medication represent common therapeutic challenges in elderly subjects. To date, there is no evidence of any effective antiageing agent.

Conclusion

This review summarizes present knowledge of age-related problems in drug action and their clinical implications for an increasingly important population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. United Nations. World Population Aging 2007. http://www.un.org/esa/population/publications/WPA2007/wpp2007.htm. Accessed 26 August 2007

  2. Aalami OO, Fang TD, Song HM, Nacamuli RP (2003) Physiological features of aging persons. Arch Surg 138:1068–1076

    PubMed  Google Scholar 

  3. Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87–96

    PubMed  CAS  Google Scholar 

  4. McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56:163–184

    PubMed  CAS  Google Scholar 

  5. Stratton MA, Salinas RC (2003) Medication management in the elderly. J Okla State Med Assoc 96:116–122

    PubMed  Google Scholar 

  6. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337–344

    PubMed  Google Scholar 

  7. Kennerfalk A, Ruigómez A, Wallander MA, Wilhelmsen L, Johansson S (2002) Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 36:797–803

    PubMed  Google Scholar 

  8. Pizzuti R, Caffari B, Binkin N, Gruppo ARGENTO (2006) Prescription drugs and the elderly: results of the Argento study. Ig Sanita Publica 62:11–26

    Google Scholar 

  9. Wolff JL, Starfield B, Anderson G (2002) Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 162:2269–2276

    PubMed  Google Scholar 

  10. Doucet J, Queneau P (2005) Adverse drug reactions in the elderly. Bull Acad Natl Med 189:1693–1707; discussion 1708–1709

    PubMed  Google Scholar 

  11. Herrlinger C, Klotz U (2001) Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 15:897–918

    PubMed  CAS  Google Scholar 

  12. Vik SA, Hogan DB, Patten SB, Johnson JA, Romonko-Slack L, Maxwell CJ (2006) Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging 23:345–356

    PubMed  Google Scholar 

  13. Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG (2005) Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med 165:68–74

    PubMed  Google Scholar 

  14. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT (2007) Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 370:173–184

    PubMed  Google Scholar 

  15. Woodhouse KW, O’Mahony MS (1997) Frailty and ageing. Age Ageing 26:245–246

    PubMed  CAS  Google Scholar 

  16. Yancik R, Ershler W, Satariano W, Hazzard W, Cohen HJ, Ferrucci L (2007) Report of the national institute on aging task force on comorbidity. J Gerontol A Biol Sci Med Sci 62:275–280

    PubMed  Google Scholar 

  17. Lash TL, Mor V, Wieland D, Ferrucci L, Satariano W, Silliman RA (2007) Methodology, design, and analytic techniques to address measurement of comorbid disease. J Gerontol A Biol Sci Med Sci 62:281–285

    PubMed  Google Scholar 

  18. Boyd CM, Weiss CO, Halter J, Han KC, Ershler WB, Fried LP (2007) Framework for evaluating disease severity measures in older adults with comorbidity. J Gerontol A Biol Sci Med Sci 62:286–295

    PubMed  Google Scholar 

  19. Karlamangla A, Tinetti M, Guralnik J, Studenski S, Wetle T, Reuben D (2007) Comorbidity in older adults: nosology of impairment, diseases, and conditions. J Gerontol A Biol Sci Med Sci 62:296–300

    PubMed  Google Scholar 

  20. Varas-Lorenzo C, Rueda de Castro AM, Maguire A, Miret M (2006) Prevalence of glucose metabolism abnormalities and cardiovascular co-morbidity in the US elderly adult population. Pharmacoepidemiol Drug Saf 15:317–326

    PubMed  Google Scholar 

  21. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233

    PubMed  Google Scholar 

  22. van der Wel MC, Jansen RW, Bakx JC, Bor HH, Olderikkert MG, van Weel C (2007) Non-cardiovascular co-morbidity in elderly patients with heart failure outnumbers cardiovascular co-morbidity. Eur J Heart Fail 9:709–715

    PubMed  Google Scholar 

  23. Cesari M, Onder G, Russo A, Zamboni V, Barillaro C, Ferrucci L, Pahor M, Bernabei R, Landi F (2006) Comorbidity and physical function: results from the aging and longevity study in the Sirente geographic area (ilSIRENTE study). Gerontology 52:24–32

    PubMed  Google Scholar 

  24. Kadam U, Croft P; North Staffordshire GP Consortium Group (2007) Clinical multimorbidity and physical function in older adults: a record and health status linkage study in general practice. Fam Pract 24:412–419

  25. Bretherton A, Day L, Lewis G (2003) Polypharmacy and older people. Nurs Times 99:54–55

    PubMed  Google Scholar 

  26. Viktil KK, Blix HS, Moger TA, Reikvam A (2007) Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 63:187–195

    PubMed  Google Scholar 

  27. Fulton MM, Allen ER (2005) Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 17:123–132

    PubMed  Google Scholar 

  28. Rosholm JU, Holm EA; Dansk Selskab for Geriatri (2007) Polypharmacy in elderly patients – the eternal problem. The Danish Geriatric Society. Ugeskr Laeger 169:1104

    Google Scholar 

  29. Rajska-Neumann A, Wieczorowska-Tobis K (2007) Polypharmacy and potential inappropriateness of pharmaco-logical treatment among community-dwelling elderly patients. Arch Gerontol Geriatr 44[Suppl 1]:303–309

    PubMed  Google Scholar 

  30. Lernfelt B, Samuelsson O, Skoog I, Landahl S (2003) Changes in drug treatment in the elderly between 1971 and 2000. Eur J Clin Pharmacol 59:637–644

    PubMed  CAS  Google Scholar 

  31. Queneau P (2006) Pitfalls of polypharmacy, particularly in the elderly. Bull Mem Acad R Med Belg 161:408–421

    PubMed  CAS  Google Scholar 

  32. Frazier SC (2005) Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs 31:4–11

    PubMed  Google Scholar 

  33. Mallet L, Spinewine A, Huang A (2007) The challenge of managing drug interactions in elderly people. Lancet 370:185–191

    PubMed  CAS  Google Scholar 

  34. Björkman IK, Fastbom J, Schmidt IK, Bernsten CB; Pharmaceutical Care of the Elderly in Europe Research (PEER) Group (2002) Drug-drug interactions in the elderly. Ann Pharmacother 36:1675–1681

    Google Scholar 

  35. Egger SS, Rätz Bravo AE, Hess L, Schlienger RG, Krähenbühl S (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24:429–440

    PubMed  CAS  Google Scholar 

  36. Dergal JM, Gold JL, Laxer DA, Lee MS, Binns MA, Lanctôt KL, Freedman M, Rochon PA (2002) Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging 19:879–886

    PubMed  CAS  Google Scholar 

  37. Yoon SL, Schaffer SD (2006) Herbal, prescribed, and over-the-counter drug use in older women: prevalence of drug interactions. Geriatr Nurs 27:118–129

    PubMed  Google Scholar 

  38. Pringle KE, Ahern FM, Heller DA, Gold CH, Brown TV (2005) Potential for alcohol and prescription drug interactions in older people. J Am Geriatr Soc 53:1930–1936

    PubMed  Google Scholar 

  39. Lindblad CI, Hanlon JT, Gross CR, Sloane RJ, Pieper CF, Hajjar ER, Ruby CM, Schmader KE (2006) Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther 28:1133–1143

    PubMed  CAS  Google Scholar 

  40. Lindblad CI, Artz MB, Pieper CF, Sloane RJ, Hajjar ER, Ruby CM, Schmader KE, Hanlon JT (2005) Potential drug-disease interactions in frail, hospitalized elderly veterans. Ann Pharmacother 39:412–417

    PubMed  Google Scholar 

  41. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289:1652–1658

    PubMed  CAS  Google Scholar 

  42. Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, Ménard JF, Bercoff E (1996) Drug–drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 44:944–948

    PubMed  CAS  Google Scholar 

  43. Levy RH, Collins C (2007) Risk and predictability of drug interactions in the elderly. Int Rev Neurobiol 81:235–251

    PubMed  CAS  Google Scholar 

  44. Zhan C, Correa-de-Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW, Stryer D (2005) Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug–disease combinations. J Am Geriatr Soc 53:262–267

    PubMed  Google Scholar 

  45. Lally F, Crome P (2007) Understanding frailty. Postgrad Med J 83:16–20

    PubMed  Google Scholar 

  46. Ahmed N, Mandel R, Fain MJ (2007) Frailty: an emerging geriatic syndrome. Amer J Med 120:748–753

    PubMed  Google Scholar 

  47. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G (2004) Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59:255–263

    PubMed  Google Scholar 

  48. Slaets JP (2006) Vulnerability in the elderly: frailty. Med Clin North Am 90:593–601

    PubMed  Google Scholar 

  49. Cawthon PM, Marshall LM, Michael Y, Dam TT, Ensrud KE, Barrett-Connor E, Orwoll ES; for the Osteoporotic Fractures in Men Research Group (2007) Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc 55:1216–1223

    Google Scholar 

  50. Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, Tracy JK, Hochberg MC, Rodondi N, Cawthon PM; the Study of Osteoporotic Fractures Research Group (2007) Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 62:744–751

    Google Scholar 

  51. Torpy JM, Lynm C, Glass RM (2006) JAMA patient page. Frailty in older adults. JAMA 296:2280

    PubMed  CAS  Google Scholar 

  52. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, Gottdiener J, Fried LP; Cardiovascular Health Study (2002) Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med 162:2333–2341

    Google Scholar 

  53. Cohen HJ, Harris T, Pieper CF (2003) Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114:180–187

    PubMed  Google Scholar 

  54. von Känel R, Dimsdale JE, Mills PJ, Ancoli-Israel S, Patterson TL, Mausbach BT, Grant I (2006) Effect of Alzheimer caregiving stress and age on frailty markers interleukin-6, C-reactive protein, and D-dimer. J Gerontol A Biol Sci Med Sci 61:963–969

    Google Scholar 

  55. Balducci L (2007) Aging, frailty, and chemotherapy. Cancer Control 14:7–12

    PubMed  Google Scholar 

  56. Gobbens RJ, Luijkx KG, Wijnen-Sponselee MT, Schols JM (2007) Frail elderly. Identification of a population at risk. Tijdschr Gerontol Geriatr 38:65–76

    PubMed  CAS  Google Scholar 

  57. Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM, Schmader KE (2006) Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 61:511–515

    PubMed  Google Scholar 

  58. Levers MJ, Estabrooks CA, Ross Kerr JC (2006) Factors contributing to frailty: literature review. J Adv Nurs 56:282–291

    PubMed  Google Scholar 

  59. Marzetti E, Leeuwenburgh C (2006) Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp Gerontol 41:1234–1238

    PubMed  CAS  Google Scholar 

  60. Janssen I (2006) Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc 54:56–62

    PubMed  Google Scholar 

  61. Di Iorio A, Abate M, Di Renzo D, Russolillo A, Battaglini C, Ripari P, Saggini R, Paganelli R, Abate G (2006) Sarcopenia: age-related skeletal muscle changes from determinants to physical disability. Int J Immunopathol Pharmacol 19:703–719

    PubMed  Google Scholar 

  62. Summerbell J, Wynne H, Hankey CR, Williams FM (1993) The effect of age and frailty upon blood esterase activities and their response to dietary supplementation. Br J Clin Pharmacol 36:399–404

    PubMed  CAS  Google Scholar 

  63. Williams FM, Wynne H, Woodhouse KW, Rawlins MD (1989) Plasma aspirin esterase: the influence of old age and frailty. Age Ageing 18:39–42

    PubMed  CAS  Google Scholar 

  64. Summerbell J, Yelland C, Woodhouse K (1990) The kinetics of plasma aspirin esterase in relation to old age and frailty. Age Ageing 19:128–130

    PubMed  CAS  Google Scholar 

  65. Wynne HA, Cope LH, Herd B, Rawlins MD, James OF, Woodhouse KW (1990) The association of age and frailty with paracetamol conjugation in man. Age Ageing 19:419–424

    PubMed  CAS  Google Scholar 

  66. Wynne HA, Yelland C, Cope LH, Boddy A, Woodhouse KW, Bateman DN (1993) The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing 22:354–359

    PubMed  CAS  Google Scholar 

  67. Groen K, Horan MA, Roberts NA, Gulati RS, Miljkovic B, Jansen EJ, Paramsothy V, Breimer DD, van Bezooijen CF (1993) The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. Clin Pharmacokinet 25:136–144

    PubMed  CAS  Google Scholar 

  68. Hughes CM (2004) Medication non-adherence in the elderly: how big is the problem? Drugs Aging 21:793–811

    PubMed  Google Scholar 

  69. Black DM, Brand RJ, Greenlick M, Hughes G, Smith J (1987) Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. J Gerontol 42:552–557

    PubMed  CAS  Google Scholar 

  70. Kuzuya M, Endo H, Umegaki H, Nakao M, Niwa T, Kumagai T, Ushida Y, Nabeshima T, Iguchi A (2000) Factors influencing noncompliance with medication regimens in the elderly. Nippon Ronen Igakkai Zasshi 37:363–370

    PubMed  CAS  Google Scholar 

  71. Kripalani S, Yao X, Haynes RB (2007) Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 167:540–550

    PubMed  Google Scholar 

  72. Topinková E, Fialová D, Carpenter GI, Bernabei R (2006) Cross-national comparison of drug compliance and non-compliance associated factors in the elderly with polypharmacotherapy. Cas Lek Ces 145:726–732

    Google Scholar 

  73. Bosworth HB, Voils CI, Potter GG, Steffens DC (2007) The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. Int J Geriatr Psychiatry 2007 June 12 (Epub ahead of print). PMID 17563920

  74. Goeman DP, Douglass JA (2007) Optimal management of asthma in elderly patients: strategies to improve adherence to recommended interventions. Drugs Aging 24:381–394

    PubMed  Google Scholar 

  75. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497

    PubMed  CAS  Google Scholar 

  76. Schneider MP, Locca JF, Bugnon O, Conzelmann M (2006) Drug compliance in the elderly: determinants and support. Rev Med Suisse 2:664–666, 669–670

    PubMed  Google Scholar 

  77. Rottlaender D, Scherner M, Schneider T, Erdmann E (2007) Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr 132:139–144

    PubMed  CAS  Google Scholar 

  78. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462–467

    PubMed  Google Scholar 

  79. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455–461

    PubMed  Google Scholar 

  80. Volmink J, Garner P (2007) WITHDRAWN: Interventions for promoting adherence to tuberculosis management. Cochrane Database Syst Rev 3:CD000010

  81. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP (2005) Interventions to enhance medication adherence. Cochrane Database Syst Rev 4:CD000011

    Google Scholar 

  82. Pastor Climente IP, Ortiz de Urbina Sandomingo V, Pérez Escoto I, Quintana Vargas I, Moreno Miralles A, Martínez Martínez M (2007) The introduction of a programme to improve the treatment compliance of institutionalised elderly patients. Farm Hosp 31:106–111

    PubMed  CAS  Google Scholar 

  83. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC (1991) Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 151:1825–1832

    PubMed  CAS  Google Scholar 

  84. Beers MH (1997) Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 157:1531–1536

    PubMed  CAS  Google Scholar 

  85. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 163:2716–2724

    PubMed  Google Scholar 

  86. Laroche ML, Charmes JP, Merle L (2007) Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol 63:725–731

    PubMed  Google Scholar 

  87. Pugh MJ, Hanlon JT, Zeber JE, Bierman A, Cornell J, Berlowitz DR (2006) Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. J Manag Care Pharm 12:537–545

    PubMed  Google Scholar 

  88. Gallagher P, Barry P, O’Mahony D (2007) Inappropriate prescribing in the elderly. J Clin Pharm Ther 32:113–121

    PubMed  CAS  Google Scholar 

  89. Johnell K, Fastbom J, Rosén M, Leimanis A (2007) Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 41:1243–1248

    PubMed  Google Scholar 

  90. Barry PJ, O’Keefe N, O’Connor KA, O’Mahony D (2006) Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther 31:617–626

    PubMed  CAS  Google Scholar 

  91. Landi F, Russo A, Liperoti R, Barillaro C, Danese P, Pahor M, Bernabei R, Onder G (2007) Impact of inappropriate drug use on physical performance among a frail elderly population living in the community. Eur J Clin Pharmacol 63:791–799

    PubMed  CAS  Google Scholar 

  92. Page RL 2nd, Ruscin JM (2006) The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother 4:297–305

    PubMed  Google Scholar 

  93. Zuckerman IH, Langenberg P, Baumgarten M, Orwig D, Byrns PJ, Simoni-Wastila L, Magaziner J (2006) Inappropriate drug use and risk of transition to nursing homes among community-dwelling older adults. Med Care 44:722–730

    PubMed  Google Scholar 

  94. Fu AZ, Jiang JZ, Reeves JH, Fincham JE, Liu GG, Perri M 3rd (2007) Potentially inappropriate medication use and healthcare expenditures in the US community-dwelling elderly. Med Care 45:472–476

    PubMed  Google Scholar 

  95. Passarelli MC, Jacob-Filho W, Figueras A (2005) Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 22:767–777

    PubMed  Google Scholar 

  96. Klarin I, Wimo A, Fastbom J (2005) The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old. Drugs Aging 22:69–82

    PubMed  Google Scholar 

  97. Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63:177–186

    PubMed  Google Scholar 

  98. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkälä KH (2006) Use of inappropriate medications and their prognostic significance among in-hospital and nursing home patients with and without dementia in Finland. Drugs Aging 23:333–343

    PubMed  Google Scholar 

  99. Rochon PA, Gurwitz JH (1997) Optimising drug treatment for elderly people: the prescribing cascade. Br Med J 315:1096–1099

    CAS  Google Scholar 

  100. Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, Shulman KI, Lee PE, Rochon PA (2005) A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 165:808–813

    PubMed  Google Scholar 

  101. Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14

    PubMed  CAS  Google Scholar 

  102. Hilmer SN, McLachlan AJ, Le Couteur DG (2007) Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 21:217–230

    PubMed  CAS  Google Scholar 

  103. Lotrich FE, Pollock BG (2005) Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 45:1106–1122

    PubMed  CAS  Google Scholar 

  104. Aronow WS, Frishman WH, Cheng-Lai A (2007) Cardiovascular drug therapy in the elderly. Cardiol Rev 15:195–215

    PubMed  Google Scholar 

  105. Feldman M (1997) The mature stomach. Still pumping out acid? JAMA 278:681–682

    PubMed  CAS  Google Scholar 

  106. Haruma K, Kamada T, Kawaguchi H, Okamoto S, Yoshihara M, Sumii K, Inoue M, Kishimoto S, Kajiyama G, Miyoshi A (2000) Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol 15:277–283

    PubMed  CAS  Google Scholar 

  107. Nakamura K, Ogoshi K, Makuuchi H (2006) Influence of aging, gastric mucosal atrophy and dietary habits on gastric secretion. Hepatogastroenterology 53:624–628

    PubMed  Google Scholar 

  108. Wiley JW (2002) Aging and neural control of the GI tract: III. Senescent enteric nervous system: lessons from extraintestinal sites and nonmammalian species. Am J Physiol Gastrointest Liver Physiol 283:G1020–G1026

    PubMed  CAS  Google Scholar 

  109. Orr WC, Chen CL (2002) Aging and neural control of the GI tract: IV. Clinical and physiological aspects of gastrointestinal motility and aging. Am J Physiol Gastrointest Liver Physiol 283:G1226–G1231

    PubMed  CAS  Google Scholar 

  110. Ciccocioppo R, Di Sabatino A, Luinetti O, Rossi M, Cifone MG, Corazza GR (2002) Small bowel enterocyte apoptosis and proliferation are increased in the elderly. Gerontology 48:204–208

    PubMed  CAS  Google Scholar 

  111. Saltzman JR, Kowdley KV, Perrone G, Russell RM (1995) Changes in small-intestine permeability with aging. J Am Geriatr Soc 43:160–164

    PubMed  CAS  Google Scholar 

  112. Kinirons MT, Crome P (1997) Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet 33:302–312

    PubMed  CAS  Google Scholar 

  113. Zeeh J, Platt D (2002) The aging liver: structural and functional changes and their consequences for drug treatment in old age. Gerontology 48:121–127

    PubMed  CAS  Google Scholar 

  114. Tateishi T, Fujimura A, Shiga T, Ohashi K, Ebihara A (1995) Influence of aging on the oxidative and conjugative metabolism of propranolol. Int J Clin Pharmacol Res 15:95–101

    PubMed  CAS  Google Scholar 

  115. Anantharaju A, Feller A, Chedid A (2002) Aging Liver. A review. Gerontology 48:343–353

    PubMed  CAS  Google Scholar 

  116. Davies RO, Gomez HJ, Irvin JD, Walker JF (1984) An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 18[Suppl 2]:215S–229S

    PubMed  Google Scholar 

  117. Dresser GK, Bailey DG, Carruthers SG (2000) Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 68:28–34

    PubMed  CAS  Google Scholar 

  118. Muriel Villoria C, Pérez-Castejón Garrote JM, Sánchez Magro I, Neira Alvarez M (2007) Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study. Med Clin (Barc) 128:204–210

    Google Scholar 

  119. Priano L, Gasco MR, Mauro A (2006) Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 23:357–375

    PubMed  CAS  Google Scholar 

  120. Ramsay SE, Whincup PH, Shaper AG, Wannamethee SG (2006) The relations of body composition and adiposity measures to ill health and physical disability in elderly men. Am J Epidemiol 164:459–469

    PubMed  Google Scholar 

  121. Tyagi R, Kapoor S, Kapoor AK (2005) Body composition and fat distribution pattern of urban elderly females, Delhi, India. Coll Antropol 29:493–498

    PubMed  Google Scholar 

  122. Forbes GB, Reina JC (1970) Adult lean body mass declines with age: some longitudinal observations. Metabolism 19:653–663

    PubMed  CAS  Google Scholar 

  123. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55:347–359

    PubMed  CAS  Google Scholar 

  124. Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 17:353–362

    PubMed  CAS  Google Scholar 

  125. Mörike K, Schwab M, Klotz U (1997) Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging 10:259–277

    PubMed  Google Scholar 

  126. Benet LZ, Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–121

    PubMed  CAS  Google Scholar 

  127. Koyama H, Mori S, Sugioka N, Nishihara T, Nakajima K (2003) Age-related alteration of haloperidol-serum protein binding. J Pharm Pharmacol 55:77–83

    PubMed  CAS  Google Scholar 

  128. Brenner SS, Herrlinger C, Dilger K, Mürdter TE, Hofmann U, Marx C, Klotz U (2003) Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 42:283–292

    PubMed  CAS  Google Scholar 

  129. Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME (2005) Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 43:227–238

    PubMed  CAS  Google Scholar 

  130. Wynne H (2005) Drug metabolism and ageing. J Br Menopause Soc 11:51–56

    PubMed  Google Scholar 

  131. Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ (2005) The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 44:187–200

    PubMed  Google Scholar 

  132. Durnas C, Loi CM, Cusack BJ (1990) Hepatic drug metabolism and aging. Clin Pharmacokinet 19:359–389

    PubMed  CAS  Google Scholar 

  133. Le Couteur DG, McLean AJ (1998) The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34:359–373

    PubMed  Google Scholar 

  134. James OF (1997) Parenchymal liver disease in the elderly. Gut 41:430–432

    PubMed  CAS  Google Scholar 

  135. Schmucker DL (2001) Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 18:837–851

    PubMed  CAS  Google Scholar 

  136. Wauthier V, Verbeeck RK, Calderon PB (2007) The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem 14:745–757

    PubMed  CAS  Google Scholar 

  137. Kinirons MT, O’Mahony MS (2004) Drug metabolism and ageing. Br J Clin Pharmacol 57:540–544

    PubMed  CAS  Google Scholar 

  138. Woodhouse KW, James OF (1990) Hepatic drug metabolism and ageing. Br Med Bull 46:22–35

    PubMed  CAS  Google Scholar 

  139. O’Connell MB, Frye RF, Matzke GR, St Peter JV, Willhite LA, Welch MR, Kowal P, LaValleur J (2006) Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol 46:1299–1307

    PubMed  CAS  Google Scholar 

  140. Dorne JL, Walton K, Slob W, Renwick AG (2002) Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem Toxicol 40:1633–1656

    PubMed  CAS  Google Scholar 

  141. Schmucker DL (1998) Aging and the liver: an update. J Gerontol A Biol Sci Med Sci 53:B315–B320

    PubMed  CAS  Google Scholar 

  142. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423

    PubMed  CAS  Google Scholar 

  143. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193–209

    PubMed  CAS  Google Scholar 

  144. Kang D, Verotta D, Schwartz JB (2006) Population analyses of amlodipine in patients living in the community and patients living in nursing homes. Clin Pharmacol Ther 79:114–124

    PubMed  CAS  Google Scholar 

  145. Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ (2007) Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 81:828–832

    PubMed  CAS  Google Scholar 

  146. Kurnik D, Wood AJ, Wilkinson GR (2006) The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 80:228–234

    PubMed  CAS  Google Scholar 

  147. Schwartz JB (2006) Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin Pharmacol Ther 79:440–448

    PubMed  CAS  Google Scholar 

  148. Dilger K, Hofmann U, Klotz U (2000) Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 67:512–520

    PubMed  CAS  Google Scholar 

  149. Platten HP, Schweizer E, Dilger K, Mikus G, Klotz U (1998) Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther 63:552–560

    PubMed  CAS  Google Scholar 

  150. Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, Schüttler J (1999) The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 65:630–639

    PubMed  CAS  Google Scholar 

  151. Mangoni AA (2007) The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opin Drug Metab Toxicol 3:315–320

    PubMed  CAS  Google Scholar 

  152. Christians U (2004) Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A. Ther Drug Monit 26:104–106

    PubMed  CAS  Google Scholar 

  153. Christians U, Schmitz V, Haschke M (2005) Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 1:641–654

    PubMed  CAS  Google Scholar 

  154. Brenner SS, Klotz U (2004) P-glycoprotein function in the elderly. Eur J Clin Pharmacol 60:97–102

    PubMed  CAS  Google Scholar 

  155. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540–548

    PubMed  CAS  Google Scholar 

  156. Beck LH (1998) Changes in renal function with aging. Clin Geriatr Med 14:199–209

    PubMed  CAS  Google Scholar 

  157. Lindeman RD, Tobin J, Shock NW (1985) Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33:278–285

    PubMed  CAS  Google Scholar 

  158. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW (1976) The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 31:155–163

    PubMed  CAS  Google Scholar 

  159. Fehrman-Ekholm I, Skeppholm L (2004) Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 38:73–77

    PubMed  CAS  Google Scholar 

  160. Froissart M, Rossert J (2005) How to improve estimation of renal function in the elderly. Rev Prat 55:2223–2229

    PubMed  Google Scholar 

  161. Fliser D, Franek E, Joest M, Block S, Mutschler E, Ritz E (1997) Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 51:1196–1204

    PubMed  CAS  Google Scholar 

  162. Fliser D, Franek E, Ritz E (1997) Renal function in the elderly–is the dogma of an inexorable decline of renal function correct? Nephrol Dial Transplant 12:1553–1555

    PubMed  CAS  Google Scholar 

  163. Laroche ML, Charmes JP, Marcheix A, Bouthier F, Merle L (2006) Estimation of glomerular filtration rate in the elderly: Cockcroft-Gault formula versus modification of diet in renal disease formula. Pharmacotherapy 26:1041–1046

    PubMed  Google Scholar 

  164. Wasén E, Isoaho R, Mattila K, Vahlberg T, Kivelä SL, Irjala K (2004) Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med 256:70–78

    PubMed  Google Scholar 

  165. Maftei ID, Cepoi V, Covic A (2007) Assessing renal function in elderly people. Rev Med Chir Soc Med Nat Iasi 111:27–38

    PubMed  Google Scholar 

  166. Lewerin C, Ljungman S, Nilsson-Ehle H (2007) Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly. J Intern Med 261:65–73

    PubMed  CAS  Google Scholar 

  167. Corsonello A, Pedone C, Corica F, Mussi C, Carbonin P, Antonelli Incalzi R; Gruppo Italiano di Farmacovigilanza nell’Anziano (GIFA) Investigators (2005). Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 165:790–795

    Google Scholar 

  168. Sproule BA, Hardy BG, Shulman KI (2000) Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 16:165–177

    PubMed  CAS  Google Scholar 

  169. Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM (2002) Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. Q J Med 95:291–297

    CAS  Google Scholar 

  170. Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, Resor SR Jr, Bazil CW (2007) Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 48:1351–1359

    PubMed  CAS  Google Scholar 

  171. Perucca E (2007) Age-related changes in pharmacokinetics: predictability and assessment methods. Int Rev Neurobiol 81:183–199

    PubMed  CAS  Google Scholar 

  172. Perucca E (2006) Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 45:351–363

    PubMed  CAS  Google Scholar 

  173. Boyd RA, Türck D, Abel RB, Sedman AJ, Bockbrader HN (1999) Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 40:474–479

    PubMed  CAS  Google Scholar 

  174. Fliser D, Bischoff I, Hanses A, Block S, Joest M, Ritz E, Mutschler E (1999) Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 55:205–211

    PubMed  CAS  Google Scholar 

  175. Meyer B, Traunmueller F, Bojic A, Locker G, Schmid R, Winkler S, Thalhammer F (2006) Single-dose pharmacokinetics of cefodizime in critically ill elderly patients. Int J Antimicrob Agents 27:335–338

    PubMed  CAS  Google Scholar 

  176. Bressler R, Bahl JJ (2003) Principles of drug therapy for the elderly patient. Mayo Clin Proc 78:1564–1577

    PubMed  CAS  Google Scholar 

  177. Jackson SH (1994) Pharmacodynamics in the elderly. J R Soc Med 87[Suppl 23]:5–7

    PubMed  Google Scholar 

  178. Lichtman SM (2007) Pharmacokinetics and pharmacodynamics in the elderly. Clin Adv Hematol Oncol 5:181–182

    PubMed  Google Scholar 

  179. Vuyk J (2003) Pharmacodynamics in the elderly. Best Pract Res Clin Anaesthesiol 17:207–218

    PubMed  CAS  Google Scholar 

  180. Tobias D (2004) Age-related changes in pharmacokinetics and pharmacodynamics: a review. Consult Pharm 19:736–739

    PubMed  Google Scholar 

  181. Shah RR (2004) Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol 58:452–469

    PubMed  Google Scholar 

  182. Schwab M, Röder F, Aleker T, Ammon S, Thon KP, Eichelbaum M, Klotz U (2000) Psychotropic drug use, falls and hip fracture in the elderly. Aging (Milano) 12:234–239

    CAS  Google Scholar 

  183. Nomura K, Nakao M, Sato M, Yano E (2007) The long-term prescription of benzodiazepines, psychotropic agents, to the elderly at a university hospital in Japan. Tohoku J Exp Med 212:239–246

    PubMed  Google Scholar 

  184. Barberá T, Avellana JA, Moreno L (2007) Are benzodiazepines correctly used in the elderly? Rev Clin Esp 207:138–140

    PubMed  Google Scholar 

  185. Mottram P, Wilson K, Strobl J (2006) Antidepressants for depressed elderly. Cochrane Database Syst Rev 25:CD003491

    Google Scholar 

  186. Sophie S (2007) Anaesthesia for the elderly patient. J Pak Med Assoc 57:196–201

    PubMed  Google Scholar 

  187. Tsui BC, Wagner A, Finucane B (2004) Regional anaesthesia in the elderly: a clinical guide. Drugs Aging 21:895–910

    PubMed  Google Scholar 

  188. Osman ES, Khafagy HF, Radwan KG, Desouky AM (2007) Role of cholinesterase activity on pharmacodynamics of mivacurium preceded by pancuronium in elderly and young adults. J Egypt Soc Parasitol 37:243–255

    PubMed  Google Scholar 

  189. Mapleson WW (1996) Effect of age on MAC in humans: a meta-analysis. Br J Anaesth 76:179–185

    PubMed  CAS  Google Scholar 

  190. Nickalls RW, Mapleson WW (2003) Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. Br J Anaesth 91:170–174

    PubMed  CAS  Google Scholar 

  191. Vestal RE, Wood AJ, Shand DG (1979) Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 26:181–186

    PubMed  CAS  Google Scholar 

  192. Connolly MJ, Crowley JJ, Charan NB, Nielson CP, Vestal RE (1995) Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest 108:401–406

    PubMed  CAS  Google Scholar 

  193. Parker AL (2004) Aging does not affect beta-agonist responsiveness after methacholine-induced bronchoconstriction. J Am Geriatr Soc 52:388–392

    PubMed  Google Scholar 

  194. Elliott HL (1988) Alpha 1-adrenoceptor responsiveness: the influence of age. J Cardiovasc Pharmacol 12[Suppl 8]:S116–S123

    PubMed  Google Scholar 

  195. Nair BR (2002) Evidence based medicine for older people: available, accessible, acceptable, adaptable? Aust J Ageing 21:58–60

    Google Scholar 

  196. Hernández-Díaz S, Rodríguez LA (2000) Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160:2093–2099

    PubMed  Google Scholar 

  197. Routledge PA, O’Mahony MS, Woodhouse KW (2004) Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57:121–126

    PubMed  CAS  Google Scholar 

  198. Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R, Gambassi G (2002) Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 50:1962–1968

    PubMed  Google Scholar 

  199. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 329:15–19

    Google Scholar 

  200. van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH (2006) Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Safety 29:161–168

    PubMed  Google Scholar 

  201. Zargarzadeh AH, Emami MH, Hosseini F (2007) Drug-related hospital admissions in a generic pharmaceutical system. Clin Exp Pharmacol Physiol 34:494–498

    PubMed  CAS  Google Scholar 

  202. Jenerowicz D, Czarnecka-Operacz M, Górecka A, Stawny M (2006) Drug-related hospital admissions–an overview of frequency and clinical presentation. Acta Pol Pharm 63:395–399

    PubMed  Google Scholar 

  203. Hitchen L (2006) Adverse drug reactions result in 250,000 UK admissions a year. Br Med J 332:1109

    Google Scholar 

  204. Burgess CL, Holman CD, Satti AG (2005) Adverse drug reactions in older Australians, 1981–2002. Med J Aust 182:267–270

    PubMed  Google Scholar 

  205. Zhang M, Holman CD, Preen DB, Brameld K (2007) Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980–2003. Br J Clin Pharmacol 63:163–170

    PubMed  Google Scholar 

  206. Beyth RJ, Shorr RI (1999) Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 14:231–239

    PubMed  CAS  Google Scholar 

  207. Stillman MJ, Stillman MT (2007) Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway. Geriatrics 62:26–34

    PubMed  Google Scholar 

  208. Lagunes-Espinosa AL, Peralta-Pedrero ML, Rodríguez-Moctezuma R, López-Carmona JM, Ibarra-Vicens E, Cruz-Avelar A, Murguía-Miranda C (2007) Characterizing the prescription of non-steroidal anti-inflammatory drugs among the elderly. Gac Med Mex 143:5–9

    PubMed  Google Scholar 

  209. Tarone RE, Blot WJ, McLaughlin JK (2004) Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 11:17–25

    PubMed  Google Scholar 

  210. Lanas A, Ferrandez A (2007) Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 24:121–131

    PubMed  CAS  Google Scholar 

  211. González-Juanatey JR, Rivera J, Gabriel Sánchez R, Reviriego Almohalla B, Casimiro C (2006) Effects of NSAID on blood pressure among hypertensive patients with a high cardiovascular risk. An Med Intern 23:420–427

    Google Scholar 

  212. Babbar JP (2007) Polypharmacy and adverse drug reactions. Psychiatr Serv 58:1011

    PubMed  Google Scholar 

  213. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161:700–706

    PubMed  Google Scholar 

  214. Nguyen JK, Fouts MM, Kotabe SE, Lo E (2006) Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 4:36–41

    PubMed  Google Scholar 

  215. Burton DG, Allen MC, Bird JL, Faragher RG (2005) Bridging the gap: ageing, pharmacokinetics and pharmacodynamics. J Pharm Pharmacol 57:671–679

    PubMed  CAS  Google Scholar 

  216. Kannus P, Khan KM, Lord SR (2006) Preventing falls among elderly people in the hospital environment. Falls and related injuries among seniors are a compelling ongoing priority for Australian health research. Med J Aust 184:372–373

    PubMed  Google Scholar 

  217. Heinze C, Halfens RJ, Dassen T (2007) Falls in German in-patients and residents over 65 years of age. J Clin Nurs 16:495–501

    PubMed  Google Scholar 

  218. Akyol AD (2007) Falls in the elderly: what can be done? Int Nurs Rev 54:191–196

    PubMed  CAS  Google Scholar 

  219. Prat-González I, Fernández-Escofet E, Martínez-Bustos S (2007) Assessment of risk of falls in the elderly through a screening protocol in primary care. Enferm Clin 17:128–133

    PubMed  Google Scholar 

  220. Zanocchi M, Pilon S, Speme S, Nicola E, Corsinovi L, Ponte E, Cerrato F, Luppino A, Martinelli E, Margolicci A, Molaschi M (2004) Falls in hospitalized elderly patients: incidence and risk factors. Recenti Prog Med 95:570–574

    PubMed  Google Scholar 

  221. Daal JO, van Lieshout JJ (2005) Falls and medications in the elderly. Neth J Med 63:91–96

    PubMed  CAS  Google Scholar 

  222. Walker PC, Alrawi A, Mitchell JF, Regal RE, Khanderia U (2005) Medication use as a risk factor for falls among hospitalized elderly patients. Am J Health Syst Pharm 62:2495–2499

    PubMed  Google Scholar 

  223. Ziere G, Dieleman JP, Hofman A, Pols HA, van der Cammen TJ, Stricker BH (2006) Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 61:218–223

    PubMed  CAS  Google Scholar 

  224. Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A (2005) Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 22:749–765

    PubMed  Google Scholar 

  225. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408:239–247

    PubMed  CAS  Google Scholar 

  226. Harman D (2006) Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci 1067:10–21

    PubMed  CAS  Google Scholar 

  227. Butler RN, Fossel M, Harman SM, Heward CB, Olshansky SJ, Perls TT, Rothman DJ, Rothman SM, Warner HR, West MD, Wright WE (2002) Is there an antiaging medicine? J Gerontol A Biol Sci Med Sci 57:B333–B338

    PubMed  Google Scholar 

  228. Fisher A, Morley JE (2002) Antiaging medicine: the good, the bad, and the ugly. J Gerontol A Biol Sci Med Sci 57:M636–M639

    PubMed  Google Scholar 

  229. Olshansky SJ, Hayflick L, Perls TT (2004) Introduction: anti-aging medicine: the hype and the reality – part II. J Gerontol Series A: Bio Sci Med Sci 59A:B649–B651

    Google Scholar 

  230. Scientific American (2002) The truth about human aging. http://www.sciam.com/article.cfm?articleID=0004F171-FE1E-1CDF-B4A8809EC588EEDF. Accessed 9 September 2007

  231. National Vital Statistics Reports. Vol. 53, No. 6, November 10, 2004. http://www.cdc.gov/nchs/data/dvs/nvsr53_06t12.pdf. Accessed 3 September 2007

  232. Grossman T (2005) Latest advances in antiaging medicine. Keio J Med 54:85–94

    PubMed  CAS  Google Scholar 

  233. Klotz U (2007) The elderly–a challenge for appropriate drug treatment. Eur J Clin Pharmacol (in press)

Download references

Acknowledgements

This work was supported by the Robert Bosch Foundation Stuttgart, Germany.

Conflict of interest statement

The authors declare no conflicts of interest.

Author information

Author notes

  1. Shaojun Shi

    Present address: Department of Pharmacy of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

Authors and Affiliations

  1. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376, Stuttgart, Germany

    Shaojun Shi & Ulrich Klotz

  2. University of Tübingen, Tübingen, Germany

    Ulrich Klotz

  3. Division of Clinical Pharmacology, University of Tübingen, Tübingen, Germany

    Klaus Mörike

Authors
  1. Shaojun Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Klaus Mörike
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrich Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Klotz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shi, S., Mörike, K. & Klotz, U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 64, 183–199 (2008). https://doi.org/10.1007/s00228-007-0422-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0422-1

Keywords

Search

Navigation